Amylyx Pharmaceuticals, Inc. announced the appointment of Camille L. Bedrosian, MD, as Chief Medical Officer (?CMO?). In this role, Dr. Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Dr. Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious diseases through successful clinical and translational research programs, including as CMO at Ultragenyx Pharmaceutical Inc. (?Ultragenyx?), Alexion Pharmaceuticals, Inc. (?Alexion?), and ARIAD Pharmaceuticals Inc. (?ARIAD?).

Amylyx? current CMO, Patrick Yeramian, MD, MBA, will stay on as an advisor through the end of the year and will then transition into retirement, as announced in December 2022. Prior to joining Amylyx, Dr. Bedrosian served most of her nearly six years at Ultragenyx as the Executive Vice President and CMO where she was responsible for leading drug development programs and supporting translational research programs. During her time, she helped Ultragenyx grow and greatly advance its many pipeline programs in rare genetic diseases to their current and exciting pivotal stages.

While CMO for Alexion, she led the development of drugs and drug candidates, including those designed to address devastating rare diseases caused by defects in the complement system for people with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Prior to Alexion, Dr. Bedrosian was CMO for ARIAD, where she led drug development and built the clinical organization. She serves as a Member of the MIT Corporation Visiting Committee for the Department of Biology.

She also currently serves on the board of directors of Crinetics Pharmaceuticals, Inc. as well as Rhythm Pharmaceuticals, Inc.